An interventional study of active tDCS and sham tDCS in Anhedonia, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-02-18.
Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Anhedonia with a site in United States — 24 open to participants now, 25 under way, none of them phase 3. Anhedonia · United States.
Among the 76 studies in Anhedonia with a site in United States, this one is the 51st largest by planned enrollment of the 67 interventional ones that give a count, is one of 10 that started in 2022, is one of 42 with no phase, reaches primary completion later than 1 of the 24 other live ones, and was the 33rd registered.
134 studies on the registry are indexed under Anhedonia; 50 are open to participants now.
Browse Anhedonia studies →24 of the 76 studies in Anhedonia with a site in United States are open now. Recruiting first, the newest first:
Florida State University · Sites in United States
Ages 18–55 · Healthy volunteers
NYU Langone Health · Sites in United States
Ages 18–65
University of Pennsylvania · Sites in United States
Ages 13–17
Ksana Health · Sites in United States
Ages 13–24
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–70 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Anhedonia studies recruiting now, 8 (19%) set no upper age limit and 33 (77%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 10 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 72 across 111 interventional studies indexed under Anhedonia.
Median enrollment 70 across the 67 interventional studies, 87 across the 9 observational. Of the 47 that completed or were terminated, 21 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 76 have an industry lead sponsor. The 10 most frequent:
The University of Texas Health Science Center, Houston is the lead sponsor of 899 studies on the registry; 214 are open to participants now.
Of its 174 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.
The University of Texas Health Science Center, Houston has 2 studies filed under Anhedonia — fewer than ten, so there is no comparison to draw.
13 of the studies in Anhedonia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05240352The University of Texas Health Science Center, HoustonDeveloping Brain Imaging Analysis Expertise for Personalizing Transcranial Electric Stimulation in Anhedonia Treatment of Patients With Bipolar Depression | 2026-12-01 |
| NCT06829953University of PittsburghGet ActivE Study for At-risk Youth | 2026-12-31 |
| NCT05282277University of North Carolina, Chapel HillExamining the Effects of Estradiol on Neural and Molecular Response to Reward | 2026-12-31 |
| NCT05920252Ksana HealthA Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide | 2026-12-31 |
| NCT06075771Emory UniversityDopaminergic Therapy for Anhedonia - 2 | 2027-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 76 studies in Anhedonia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate whether transcranial direct-current stimulation (tDCS) will engage reward-related brain circuitry, more specifically the uncinate fasciculus (UF) tract, which connects the orbitofrontal cortex (OFC) and nucleus accumbens (NAcc) regions. Also to evaluate whether the changes in the fractional anisotropy (FA) of the UF tract are associated with changes of clinical symptoms of anhedonia and finally to investigate the moderation role of simulated electric fields (EFs) in an association between FA of the UF and symptoms of anhedonia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: active tDCS
Device: sham tDCS
Subjects will receive active dose (constant current intensity of 2mA) from the tDCS device for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later
Subjects will receive a dose from a "sham-tDCS"that is, a device which delivers a different pattern of electric current for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later
change in the fractional anisotropy of the uncinate fasciculus
Change in the fractional anisotropy of the uncinate fasciculus as assessed by diffusion tensor imaging (DTI)
Time frame: baseline, 6 weeks
changes in symptoms of anhedonia as assessed by the Snaith-Hamilton Pleasure Scale modified for clinical administration (SHAPS-C)
This is a 14 item questionnaire and each is scored from 1 to 4 (1 = Lots of pleasure, 4 = No pleasure)
Time frame: baseline, 6 weeks
change in symptoms of anticipatory anhedonia as assessed by the Temporal Experience of Pleasure Scale (TEPS)
The TEPS presents 18 items, 10 of them related to the experience of anticipatory pleasure, and the other 8 related to the ability to experience pleasure at the moment. This is scored on a 6-point Likert scale (1 = very false for me to 6 = very true for me).Total scores vary form 18-108 and lower scores mean higher anhedonia
Time frame: baseline, 6 weeks
change in symptoms of consummatory anhedonia as assessed by the Temporal Experience of Pleasure Scale (TEPS)
The TEPS presents 18 items, 10 of them related to the experience of anticipatory pleasure, and the other 8 related to the ability to experience pleasure at the moment. This is scored on a 6-point Likert scale (1 = very false for me to 6 = very true for me).Total scores vary form 18-108 and lower scores mean higher anhedonia
Time frame: baseline, 6 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Dec 2026, 49 months after the start.
Of 58 non-industry interventional studies with no phase under Anhedonia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 46. This study's planned 49 months is above that.
Counting every sponsor, half of 65 studies reached it within 26 months; a quarter within 14 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of Texas Health Science Center, Houston →